Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
106 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Primary Biliary Cirrhosis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H2 2017, provides an overview of the Primary Biliary Cirrhosis (Gastrointestinal) pipeline landscape. Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0 and Preclinical stages are 1, 11, 5, 1 and 1 respectively. Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Primary Biliary Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Primary Biliary Cirrhosis - Overview Primary Biliary Cirrhosis - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Primary Biliary Cirrhosis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Primary Biliary Cirrhosis - Companies Involved in Therapeutics Development Albireo Pharma Inc Arena Pharmaceuticals Inc CymaBay Therapeutics Inc Eisai Co Ltd Enanta Pharmaceuticals Inc Genfit SA GenKyoTex SA Gilead Sciences Inc GlaxoSmithKline Plc Intercept Pharmaceuticals Inc MediGene AG NGM Biopharmaceuticals Inc Novartis AG Retrophin Inc Shire Plc Tiziana Life Sciences Plc Virobay Inc Zydus Cadila Healthcare Ltd Primary Biliary Cirrhosis - Drug Profiles A-4250 - Drug Profile Product Description Mechanism Of Action R&D Progress E-6011 - Drug Profile Product Description Mechanism Of Action R&D Progress EDP-305 - Drug Profile Product Description Mechanism Of Action R&D Progress elafibranor - Drug Profile Product Description Mechanism Of Action R&D Progress etrasimod arginine - Drug Profile Product Description Mechanism Of Action R&D Progress FFP-104 - Drug Profile Product Description Mechanism Of Action R&D Progress foralumab - Drug Profile Product Description Mechanism Of Action R&D Progress GKT-831 - Drug Profile Product Description Mechanism Of Action R&D Progress GS-9674 - Drug Profile Product Description Mechanism Of Action R&D Progress GSK-2330672 - Drug Profile Product Description Mechanism Of Action R&D Progress LJN-452 - Drug Profile Product Description Mechanism Of Action R&D Progress maralixibat chloride - Drug Profile Product Description Mechanism Of Action R&D Progress NGM-282 - Drug Profile Product Description Mechanism Of Action R&D Progress obeticholic acid - Drug Profile Product Description Mechanism Of Action R&D Progress RhuDex - Drug Profile Product Description Mechanism Of Action R&D Progress saroglitazar - Drug Profile Product Description Mechanism Of Action R&D Progress seladelpar lysine - Drug Profile Product Description Mechanism Of Action R&D Progress ursodiol - Drug Profile Product Description Mechanism Of Action R&D Progress VBY-825 - Drug Profile Product Description Mechanism Of Action R&D Progress Primary Biliary Cirrhosis - Dormant Projects Primary Biliary Cirrhosis - Product Development Milestones Featured News & Press Releases Jun 27, 2017: Genkyotex Initiates Patient Enrollment into Phase 2 Trial of GKT831 in Primary Biliary Cholangitis May 02, 2017: Genkyotex Announces FDA Approval of IND for Phase 2 Trial of GKT831 in Patients with Primary Biliary Cholangitis Apr 19, 2017: Intercept Announces New Ocaliva (obeticholic acid) and INT-767 Data to be Presented at EASL 2017 Apr 05, 2017: Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress 2017 Feb 23, 2017: Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis Nov 04, 2016: GENFIT: FDA has officially cleared the IND to proceed with Phase II trial and evaluate elafibranor in PBC Oct 20, 2016: CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With Primary Biliary Cholangitis at the AASLD 2016 Liver Meeting Oct 20, 2016: CymaBay Therapeutics Announces that MBX-8025 has Received European Medicines Agency PRIority MEdicines Designation for the Treatment of Primary Biliary Cholangitis Oct 05, 2016: CymaBay Therapeutics Announces Plans to Initiate Its Next Phase 2 Study of MBX-8025 in Primary Biliary Cholangitis Aug 17, 2016: New England Journal of Medicine Publishes Results of Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC May 31, 2016: CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC) May 27, 2016: FDA Grants Accelerated Approval to Ocaliva (Obeticholic Acid) for the Treatment of Patients with PBC May 18, 2016: Intercept Announces Ocaliva (Obeticholic Acid) Data in PBC to be Presented at DDW 2016 Apr 14, 2016: New Analyses of the Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC Presented at EASL Apr 07, 2016: FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva (obeticholic acid) for the Treatment of PBC Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Primary Biliary Cirrhosis, H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Primary Biliary Cirrhosis - Pipeline by Albireo Pharma Inc, H2 2017 Primary Biliary Cirrhosis - Pipeline by Arena Pharmaceuticals Inc, H2 2017 Primary Biliary Cirrhosis - Pipeline by CymaBay Therapeutics Inc, H2 2017 Primary Biliary Cirrhosis - Pipeline by Eisai Co Ltd, H2 2017 Primary Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals Inc, H2 2017 Primary Biliary Cirrhosis - Pipeline by Genfit SA, H2 2017 Primary Biliary Cirrhosis - Pipeline by GenKyoTex SA, H2 2017 Primary Biliary Cirrhosis - Pipeline by Gilead Sciences Inc, H2 2017 Primary Biliary Cirrhosis - Pipeline by GlaxoSmithKline Plc, H2 2017 Primary Biliary Cirrhosis - Pipeline by Intercept Pharmaceuticals Inc, H2 2017 Primary Biliary Cirrhosis - Pipeline by MediGene AG, H2 2017 Primary Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals Inc, H2 2017 Primary Biliary Cirrhosis - Pipeline by Novartis AG, H2 2017 Primary Biliary Cirrhosis - Pipeline by Retrophin Inc, H2 2017 Primary Biliary Cirrhosis - Pipeline by Shire Plc, H2 2017 Primary Biliary Cirrhosis - Pipeline by Tiziana Life Sciences Plc, H2 2017 Primary Biliary Cirrhosis - Pipeline by Virobay Inc, H2 2017 Primary Biliary Cirrhosis - Pipeline by Zydus Cadila Healthcare Ltd, H2 2017 Primary Biliary Cirrhosis - Dormant Projects, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
